{
    "4 7 2025": {
        "importantArticles": [
            {
                "headline": "(Bloomberg) -- Drug manufacturers are rushing to reshape their supply chains amid President Donald Trump\u2019s escalating tariff threats, leading to a potential windfall for contractors that make medications in the US.Most Read from BloombergHousing Agency Aims to Relocate Its DC HeadquartersThis Skinny Mexico City Tower Is Just 14 Feet Wide on One SideThe Irish Hot Press Is the Low-Tech Laundry Trick the World NeedsBoston Mayor Wu Embraces Trump Resistance as Campaign Heats UpTrump Order on CDFI Fu",
                "publication_date": "2025-04-07T19:18:12.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.8271",
                "source": "Bloomberg",
                "ticker": "PFE",
                "title": "Trump\u2019s Tariff Threat Sparks Race to Find US Drug Manufacturers",
                "url": "https://finance.yahoo.com/news/trump-tariff-threat-sparks-race-191812489.html"
            },
            {
                "headline": "(Bloomberg) -- Drug manufacturers are rushing to reshape their supply chains amid President Donald Trump\u2019s escalating tariff threats, leading to a potential windfall for contractors that make medications in the US.Most Read from BloombergHousing Agency Aims to Relocate Its DC HeadquartersThis Skinny Mexico City Tower Is Just 14 Feet Wide on One SideThe Irish Hot Press Is the Low-Tech Laundry Trick the World NeedsBoston Mayor Wu Embraces Trump Resistance as Campaign Heats UpTrump Order on CDFI Fu",
                "publication_date": "2025-04-07T19:18:12.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.8271",
                "source": "Bloomberg",
                "ticker": "PFE",
                "title": "Trump\u2019s Tariff Threat Sparks Race to Find US Drug Manufacturers",
                "url": "https://finance.yahoo.com/news/trump-tariff-threat-sparks-race-191812489.html"
            }
        ],
        "avgScore": -0.8271
    },
    "4 4 2025": {
        "importantArticles": [
            {
                "headline": "FDA approves SNY's hemophilia therapy, fitusiran, and NVS' rare kidney disease drug, Vanrafia.",
                "publication_date": "2025-04-04T13:46:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4019",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure",
                "url": "https://finance.yahoo.com/news/pharma-stock-roundup-fda-nod-134600557.html"
            },
            {
                "headline": "Johnson & Johnson and Pfizer are part of the Zacks top Analyst Blog",
                "publication_date": "2025-04-04T13:04:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2023",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "The Zacks Analyst Blog Highlights Johnson & Johnson and Pfizer",
                "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-johnson-130400151.html"
            },
            {
                "headline": "We recently published a list of Jim Cramer\u2019s Lightning Round: 8 Stocks in Focus. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks that Jim Cramer discusses. Jim Cramer, host of Mad Money, discussed on Monday how investor sentiment surrounding tech stocks has shifted over [\u2026]",
                "publication_date": "2025-04-04T14:45:29.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.4939",
                "source": "Insider Monkey",
                "ticker": "PFE",
                "title": "Pfizer Inc. (PFE) \u2013 Jim Cramer Declares: \u2018Dead Money \u2013 Close the Casket!\u2019",
                "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-jim-cramer-144529049.html"
            },
            {
                "headline": "Is Pfizer stock a sell now after HHS fired thousands of employees, putting new drug approvals in limbo?",
                "publication_date": "2025-04-04T12:00:19.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5574",
                "source": "Investor's Business Daily",
                "ticker": "PFE",
                "title": "Is Pfizer Stock A Sell As HHS Firings, Tariffs Cast A Pall On Pharma?",
                "url": "https://finance.yahoo.com/m/9a6f7dfd-febf-37fb-912a-e0504d778fbc/is-pfizer-stock-a-sell-as-hhs.html"
            },
            {
                "headline": "We recently published a list of Jim Cramer\u2019s Lightning Round: 8 Stocks in Focus. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks that Jim Cramer discusses. Jim Cramer, host of Mad Money, discussed on Monday how investor sentiment surrounding tech stocks has shifted over [\u2026]",
                "publication_date": "2025-04-04T14:45:29.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.4939",
                "source": "Insider Monkey",
                "ticker": "PFE",
                "title": "Pfizer Inc. (PFE) \u2013 Jim Cramer Declares: \u2018Dead Money \u2013 Close the Casket!\u2019",
                "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-jim-cramer-144529049.html"
            },
            {
                "headline": "Johnson & Johnson and Pfizer are part of the Zacks top Analyst Blog",
                "publication_date": "2025-04-04T13:04:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2023",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "The Zacks Analyst Blog Highlights Johnson & Johnson and Pfizer",
                "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-johnson-130400151.html"
            }
        ],
        "avgScore": -0.11177500000000001
    },
    "4 3 2025": {
        "importantArticles": [
            {
                "headline": "In 2020, many companies tried to develop effective coronavirus vaccines, but two ended up succeeding and dominating the field: Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA).  If Pfizer and Moderna can bounce back, purchasing their shares now might be a great move -- but which is the more attractive option?  Pfizer has made important moves in the past few years that could pay off down the line.",
                "publication_date": "2025-04-03T12:30:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9577",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "Better Beaten-Down Stock to Buy: Pfizer Vs. Moderna",
                "url": "https://finance.yahoo.com/news/better-beaten-down-stock-buy-123000684.html"
            },
            {
                "headline": "Buying stock in great companies when they are dealing with some short-term issue that creates stock price weakness can set investors up for big gains down the road.  As long as the business is still in good shape, adding it to your portfolio when it's trading at a sizable discount can look like a brilliant move in the future.  Stocks normally trade at discounts when there are concerns or question marks about the company's future performance.",
                "publication_date": "2025-04-03T08:40:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9325",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "2 Absurdly Cheap Stocks to Buy and Hold for Years",
                "url": "https://finance.yahoo.com/news/2-absurdly-cheap-stocks-buy-084000763.html"
            },
            {
                "headline": "Both JNJ & PFE expect their sales and profits to improve in 2025.",
                "publication_date": "2025-04-03T13:59:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7003",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "JNJ vs. PFE: Which Drug Giant is a Better Buy Now?",
                "url": "https://finance.yahoo.com/news/jnj-vs-pfe-drug-giant-135900061.html"
            },
            {
                "headline": "(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK's patent rights in its competing RSV shot Arexvy, according to a Thursday filing in Delaware federal court.  GSK and Pfizer said in the filing that they would dismiss the case with prejudice, which means it cannot be refiled.  GSK, Pfizer and Moderna have developed RSV shots approved by the U.S. Food and Drug Administration, with GSK's Arexvy responsible for the majority of U.S. RSV vaccine sales.",
                "publication_date": "2025-04-03T22:03:17.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.34",
                "source": "Reuters",
                "ticker": "PFE",
                "title": "GSK resolves patent lawsuit against Pfizer over RSV vaccines",
                "url": "https://finance.yahoo.com/news/gsk-resolves-patent-lawsuit-against-220317477.html"
            },
            {
                "headline": "Pfizer's (NYSE: PFE) share price has fallen more than the S&P 500 so far this year.  If you're a growth investor, you probably won't be interested in buying Pfizer stock.  Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb.",
                "publication_date": "2025-04-03T09:47:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0108",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "Is Pfizer Stock a Buy?",
                "url": "https://finance.yahoo.com/news/pfizer-stock-buy-094700982.html"
            },
            {
                "headline": "GoodRx is trying to help pharmacies compete in a digital age, where they already face pressure on their margins.",
                "publication_date": "2025-04-03T13:00:44.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.128",
                "source": "Yahoo Finance",
                "ticker": "PFE",
                "title": "GoodRx launches new e-commerce experience for prescriptions",
                "url": "https://finance.yahoo.com/news/goodrx-launches-new-e-commerce-experience-for-prescriptions-130044902.html"
            }
        ],
        "avgScore": 0.3982166666666667
    },
    "4 2 2025": {
        "importantArticles": [
            {
                "headline": "Drugmakers breathed a sigh of relief Wednesday after President Trump didn\u2019t announce pharmaceutical tariffs.  Plus, language in the executive order indicated medicines were exempted from the reciprocal tariffs that Trump did announce.  Drugmakers were combing over the executive order to clarify the exemption language in the executive order and to make sure they won\u2019t be hit by any other tariff provisions, such as the 10% \u201cbaseline\u201d tariff.",
                "publication_date": "2025-04-02T22:03:35.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6705",
                "source": "The Wall Street Journal",
                "ticker": "PFE",
                "title": "Big Pharma Avoids Worst-Case Tariff Scenario",
                "url": "https://finance.yahoo.com/m/06d142db-a905-336a-a0df-f505312c37de/big-pharma-avoids-worst-case.html"
            },
            {
                "headline": "(Reuters) -Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation at its upcoming annual meeting, citing concerns about certain changes made to long-term awards to its CEO and others.  The modifications, including repeated changes to Pfizer's cash flow targets, and a lack of clarity about certain pipeline goals are concerning and undermine a \"pay-for-performance philosophy\", ISS said.  Annual incentives for executives are tied to achieving three financial goals, and payouts can be 30 percentage points higher or lower based on pipeline and ESG-related goals achieved, ISS said.",
                "publication_date": "2025-04-02T13:10:20.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5574",
                "source": "Reuters",
                "ticker": "PFE",
                "title": "Proxy adviser ISS recommends against Pfizer executive pay proposal",
                "url": "https://finance.yahoo.com/news/proxy-adviser-iss-recommends-pfizer-131020223.html"
            },
            {
                "headline": "The latest decision makes Pfizer's Abrysvo the first RSV vaccine approved for use in non-pregnant adults under 50 years of age in the EU.",
                "publication_date": "2025-04-02T11:37:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4215",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "PFE Secures EU Nod for Expanded Use of RSV Vaccine Abrysvo",
                "url": "https://finance.yahoo.com/news/pfe-secures-eu-nod-expanded-113700365.html"
            },
            {
                "headline": "Stocks of PFE, MRK, ABBV, LLY and others declined on Tuesday due to uncertainty surrounding Trump's proposed tariffs on pharma imports.",
                "publication_date": "2025-04-02T13:43:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.34",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "PFE, MRK, LLY & Other Drug Stocks Down Amid Tariff Jitters",
                "url": "https://finance.yahoo.com/news/pfe-mrk-lly-other-drug-134300035.html"
            },
            {
                "headline": "Pfizer\u2019s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The pharmaceutical giant, best known for its COVID-19 products (Paxlovid and Comirnaty), Eliquis, and Prevnar, a pneumococcal vaccine, has been dealing with difficult year-over-year comps due to a withering COVID-19 portfolio. Moreover, many of Pfizer\u2019s products, like Eliquis (2027 to 2029) and Ibrance (2027), face \u201cpatent cliffs.\u201d That means their time for market exclusivity is",
                "publication_date": "2025-04-02T16:43:24.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "-0.0258",
                "source": "TipRanks",
                "ticker": "PFE",
                "title": "Potential Stock Woe Ahead as Pfizer (PFE) Riles Donald Trump",
                "url": "https://finance.yahoo.com/news/potential-stock-woe-ahead-pfizer-164324539.html"
            },
            {
                "headline": "In the closing of the recent trading day, Pfizer (PFE) stood at $24.70, denoting a +0.65% change from the preceding trading day.",
                "publication_date": "2025-04-02T21:45:15.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Pfizer (PFE) Increases Yet Falls Behind Market: What Investors Need to Know",
                "url": "https://finance.yahoo.com/news/pfizer-pfe-increases-yet-falls-214515191.html"
            }
        ],
        "avgScore": 0.2131375
    },
    "4 1 2025": {
        "importantArticles": [
            {
                "headline": "Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "publication_date": "2025-04-01T16:10:13.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6597",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?",
                "url": "https://finance.yahoo.com/news/pfizer-pfe-beat-estimates-again-161013995.html"
            },
            {
                "headline": "March winds bring April showers.  Seriously, there are several great ultra-high-yield dividend stocks to buy in April.  Ares Capital (NASDAQ: ARCC) offers such a high dividend yield, at 8.68%, that you might wonder if it's sustainable.",
                "publication_date": "2025-04-01T09:50:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5267",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "3 Ultra-High-Yield Dividend Stocks to Buy in April",
                "url": "https://finance.yahoo.com/news/3-ultra-high-yield-dividend-095000907.html"
            },
            {
                "headline": "Many investor eyes were on the pharmaceutical industry on Tuesday, and not necessarily for the right reasons.  The Trump administration's promised tariffs were set to go into effect the following day, and the sector has been mentioned as a key area of focus for these.  Major stocks in the sector took notable hits, including but not at all limited to Pfizer (NYSE: PFE), Merck (NYSE: MRK), and Eli Lilly (NYSE: LLY).",
                "publication_date": "2025-04-01T23:09:39.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4116",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "Why Major Pharmaceutical Stocks Tumbled on Tuesday",
                "url": "https://finance.yahoo.com/news/why-major-pharmaceutical-stocks-tumbled-230939016.html"
            },
            {
                "headline": "NEW YORK, April 01, 2025--Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO\u00ae, the company\u2019s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, to extend the indication to include prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age. This expands the previous authorization for individuals aged 60 and older, and ABRYSVO now of",
                "publication_date": "2025-04-01T07:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "-0.0258",
                "source": "Business Wire",
                "ticker": "PFE",
                "title": "European Commission Approves Pfizer\u2019s RSV Vaccine ABRYSVO\u00ae to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease",
                "url": "https://finance.yahoo.com/news/european-commission-approves-pfizer-rsv-070000511.html"
            },
            {
                "headline": "We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other most undervalued healthcare stocks to buy according to analysts. Rising Healthcare Costs and the Impact of Tariffs on US-China Trade in [\u2026]",
                "publication_date": "2025-04-01T14:01:33.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Insider Monkey",
                "ticker": "PFE",
                "title": "Is Pfizer Inc. (PFE) the Most Undervalued Healthcare Stock to Buy According to Analysts?",
                "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-most-undervalued-140133307.html"
            },
            {
                "headline": "Dr. Mikael Dolsten, Pfizer\u2019s former chief scientific officer, is embarking on a journey of curiosity and interconnectedness in his post-Big Pharma career.",
                "publication_date": "2025-04-01T08:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Pharma Voice",
                "ticker": "PFE",
                "title": "Former Pfizer CSO Mikael Dolsten on writing his next chapter, embracing AI and asking the \u2018big questions\u2019",
                "url": "https://finance.yahoo.com/news/former-pfizer-cso-mikael-dolsten-080000530.html"
            }
        ],
        "avgScore": 0.21872499999999997
    },
    "coef": -0.3655960193861415,
    "avgCoef": 0.14157822026003775
}